Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus

Vaccine

Volumn 35, Issue 33, 2017, Pages 4287-4294

  Yang, Ming ^a   Dent, Matthew ^a   Lai, Huafang ^a   Sun, Haiyan ^a   Chen, Qiang ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Antibody dependent enhancement (ADE); Antigen; Domain III (DIII); Envelope protein; Neutralizing immunity; Vaccine; Zika virus

Indexed keywords

FC RECEPTOR; UNCLASSIFIED DRUG; ZIKA VIRUS VACCINE; ZIKV EDIII VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

AFFINITY CHROMATOGRAPHY; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CONFORMATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN SECRETION; SPLEEN CELL; ZIKA FEVER; ANIMAL; BLOOD; C57BL MOUSE; IMMUNOLOGY; MONONUCLEAR CELL; PROTEIN DOMAIN; SECRETION (PROCESS); SPLEEN; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MICE, INBRED C57BL; PROTEIN DOMAINS; SPLEEN; VACCINES, SUBUNIT; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85021384039     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.04.052     Document Type: Article

References (35)

1. Lazear, H.M., Diamond, M.S., Zika virus: new clinical syndromes and its emergence in the western hemisphere. J Virol 90 (2016), 4864–4875.
2. Attar N. ZIKA virus circulates in new regions. Nat Rev Micro 2016;14:62.
3. Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet 387 (2016), 1531–1539.
4. Samarasekera, U., Triunfol, M., Concern over Zika virus grips the world. The Lancet 387 (2016), 521–524.
5. Dai, L., Song, J., Lu, X., Deng, Y.Q., Musyoki, A.M., Cheng, H., et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19 (2016), 696–704.
6. Oliphant, T., Engle, M., Nybakken, G., Doane, C., Johnson, S., Huang, L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11 (2005), 522–530.
7. Sukupolvi-Petty, S., Austin, S.K., Engle, M., Brien, J.D., Dowd, K.A., Williams, K.L., et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84 (2010), 9227–9239.
8. Zhao, H., Fernandez, E., Dowd Kimberly, A., Speer Scott, D., Platt Derek, J., Gorman Matthew, J., et al. Structural basis of Zika virus-specific antibody protection. Cell 166 (2016), 1016–1027.
9. Belmusto-Worn, V.E., Sanchez, J.L., McCarthy, K., Nichols, R., Bautista, C.T., Magill, A.J., et al. Randomized, double-blind, phase III. Pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in healthy infants and children in Peru. Am J Trop Med Hyg 72 (2005), 189–197.
10. Heinz, F.X., Holzmann, H., Essl, A., Kundi, M., Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25 (2007), 7559–7567.
11. Lai, H., He, J., Hurtado, J., Stahnke, J., Fuchs, A., Mehlhop, E., et al. Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants. Plant Biotechnol J 12 (2014), 1098–1107.
12. He, J., Peng, L., Lai, H., Hurtado, J., Stahnke, J., Chen, Q., A plant-produced antigen elicits potent immune responses against West Nile virus in mice. Biomed Res Int, 2014, 2014, 10.
13. Lai, H., He, J., Engle, M., Diamond, M.S., Chen, Q., Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol J 10 (2012), 95–104.
14. Santi, L., Batchelor, L., Huang, Z., Hjelm, B., Kilbourne, J., Arntzen, C.J., et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26 (2008), 1846–1854.
15. Dent, M., Hurtado, J., Paul, A.M., Sun, H., Lai, H., Yang, M., et al. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J Gen Virol 97 (2016), 3280–3290.
16. Jungblut M, Oeltze K, Zehnter I, Hasselmann D, Bosio A. Preparation of Single-Cell Suspensions from Mouse Spleen with the gentleMACS Dissociator; 2008:e1029.
17. Lai, H., Engle, M., Fuchs, A., Keller, T., Johnson, S., Gorlatov, S., et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A 107 (2010), 2419–2424.
18. Crill, W.D., Chang, G.J., Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78 (2004), 13975–13986.
19. Larocca, R.A., Abbink, P., Peron, J.P.S., de A. Zanotto, P.M., Iampietro, M.J., Badamchi-Zadeh, A., et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478.
20. Abbink, P., Larocca, R.A., De La Barrera, R.A., Bricault, C.A., Moseley, E.T., Boyd, M., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science, 353, 2016, 1129.
21. Hombach, J., Solomon, T., Kurane, I., Jacobson, J., Wood, D., Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23 (2005), 5205–5211.
22. Kreil, T.R., Burger, I., Bachmann, M., Fraiss, S., Eibl, M.M., Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 110 (1997), 358–361.
23. Mason, R.A., Tauraso, N.M., Spertzel, R.O., Ginn, R.K., Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25 (1973), 539–544.
24. Demento, S.L., Bonafe, N., Cui, W., Kaech, S.M., Caplan, M.J., Fikrig, E., et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 185 (2010), 2989–2997.
25. Foged, C., Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Therap Deliv 2 (2011), 1057–1077.
26. Mayer, A., Sharma, S.K., Tolner, B., Minton, N.P., Purdy, D., Amlot, P., et al. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer 90 (2004), 2402–2410.
27. Ballou, W.R., Arevalo-Herrera, M., Carucci, D., Richie, T.L., Corradin, G., Diggs, C., et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71 (2004), 239–247.
28. Morens, D.M., Antibody-dependent of enhancement of infection and the pathogenesis of viral disease. Clin Inf Dis 19 (1994), 500–512.
29. Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiology spectrum; 2014:2.
30. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol; 2016 [advance online publication].
31. Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature 536 (2016), 48–53.
32. Stettler, K., Beltramello, M., Espinosa, D.A., Graham, V., Cassotta, A., Bianchi, S., et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science, 353, 2016, 823.
33. Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352 (2016), 467–470.
34. Beltramello, M., Williams, K.L., Simmons, C.P., Macagno, A., Simonelli, L., Quyen Nguyen Than, H., et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8 (2010), 271–283.
35. Lin, H.E., Tsai, W.Y., Liu, I.J., Li, P.C., Liao, M.Y., Tsai, J.J., et al. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis, 6, 2012, e1447.